WorldStage– Leading healthcare and pharmaceutical giant May & Baker Nigeria Plc has officially notified the Nigerian Exchange Limited (NGX) and the investing public of its upcoming board meeting.
According to the official regulatory filing signed by Adetoun Abiru (Mrs.) for Marina Nominees Limited (Company Secretaries), the board will convene on October 28, 2026. The primary objective of the session is to review, consider, and approve the company’s Unaudited Financial Statements (UFS) for the third quarter (Q3) ended September 30, 2026.
Key Takeaways for Investors & Market Stakeholders
Board Meeting Date: October 28, 2026
Financial Period: Third Quarter (Q3) ended September 30, 2026
Closed Period Status: Active since Thursday, October 1, 2026
Trading Restriction Lift: Exactly twenty-four (24) hours after the Q3 accounts are submitted to the NGX
Strict Enforcement of the Closed Period
In compliance with the post-listing rules of the Nigerian Exchange Limited (NGX), May & Baker Nigeria Plc has enforced a strict closed period.
Commencement: The trading restriction took effect on Thursday, October 1, 2026.
Scope: All insiders, directors, audit committee members, key management personnel, and connected persons are prohibited from buying or selling shares of May & Baker Nigeria Plc.
Lifting of Restriction: The closed period will officially lift twenty-four (24) hours after the approved Q3 2026 financial statements are successfully filed and uploaded to the NGX exchange platform.
Market Outlook & Corporate Governance
As macroeconomic conditions continue to influence the fast-moving consumer goods (FMCG) and pharmaceutical sectors in Nigeria, market analysts and equity investors will be closely monitoring May & Baker’s Q3 performance metrics—particularly revenue growth trends, cost containment strategies, and foreign exchange exposure management.
